Introduction {#sec1-1}
============

Alzheimer\'s disease (AD), an age-related neurodegenerative disease, is the most common cause of dementia (Kumar et al., 2015). Hyperphosphorylation of tau protein generates neuritic plaques comprising amyloid-β and neurofibrillary tangles, which are characteristics of AD (Anand et al., 2014). A cholinergic deficit, particularly in basal forebrain, together with a decrease in acetylcholine promotes cognitive impairment (Schliebs and Arendt, 2011). In addition, the presence of acetylcholinesterase (AChE), results in a decline in cholinergic transmission (Mesulam, 2013). Currently, primary treatment for AD is a cholinergic replacement therapy based on AChE inhibitors, such as donepezil, galantamine, and rivastigmine (Zemek et al., 2014).

Scopolamine, a muscarinic acetylcholine receptor antagonist used in animal models and in humans (Bajo et al., 2015; Ghumatkar et al., 2015; Alvarez-Jimenez et al., 2016), induces cognitive impairment, which is associated with an attenuation of cholinergic neurotransmission as well as an increase in oxidant stress and inflammation (Kwon et al., 2010; Min et al., 2015; Balaban et al., 2017). Scopolamine has been employed in *in vitro* testing of new compounds, especially those from natural products, for their potential to restore cognitive impairment. For example, scopolamine causes cytotoxicity and downregulation of neuronal and glial cell markers in neuronal (IMR32) and C6 glioma cells respectively, properties that are reversed upon treatment of an alcoholic extract of Ashwagandha leaves (Konar et al., 2011). Pandareesh and Anand (2013) demonstrated that pre-treatment with *Bacopa monniera* extract protects against scopolamine-induced damage in rat phochromocytoma PC12 cell line associated with upregulation of AChE and downregulation of brain-derived neurotrophic factor. Lee et al. (2014) reported that sulforaphane (10 or 20 μM), an organosulfur compound present in cruciferous vegetables, attenuates acetylcholine and choline acetyltransferase (ChAT) expression in scopolamine-treated primary mouse cortical neurons.

*N*-benzylcinnamide (PT-3), purified from *Piper submultinerve*, has been shown to exhibit neuroprotective properties against amyloid-β-induced neuronal toxicity in rat cortical primary cell culture (Thangnipon et al., 2013). PT-3 treatment also improves spatial learning and memory of aged rats through impacting on parameters associated with oxidant stress, inflammation, apoptosis, and AChE activity (Thangnipon et al., 2015). In addition, PT-3, in combination with bone morphogenetic protein 9, induces neuronal differentiation of human amniotic fluid mesenchymal stem cells by enhancing β-III tubulin-containing cell numbers and ChAT content (Thangnipon et al., 2016).

Hence, in this study, we investigated the neuroprotective mechanisms of PT-3 against scopolamine-induced cholinergic dysfunction in human neuroblastoma SH-SY5Y cell line.

Materials and Methods {#sec1-2}
=====================

Chemicals and reagents {#sec2-1}
----------------------

Unless otherwise indicated, media and supplements used for cell culture were obtained from Gibco (Carlsbad, CA, USA). Scopolamine hydrobromide, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA), 5,5′-dithio-*bis*-(2-nitrobenzoic acid) (DTNB), acetylthiocholine iodine and Bradford reagent were from Sigma (St. Louis, MO, USA). Rabbit anti-ChAT antibody was from Abcam (Cambridge, MA, USA) and other primary and secondary antibodies were from Cell Signalling Technology (Cell Signalling Technology Inc., MA, USA).

Cell culture and treatment {#sec2-2}
--------------------------

Human neuroblastoma SH-SY5Y cell line was a kind gift from Dr. Martin Broadstock (Wolfson Centre for Age Related Diseases, King\'s College London, UK). Cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C under a humidified atmosphere of 5% CO~2~ and 95% air. At 80--90% confluence, cells were treated with 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) and plated onto a 96- or 24-well plate at a density of 2 × 10^5^ cells/mL. Culture medium was changed to serum-free DMEM (Huang et al., 2014) supplemented with 50--200 nM of PT-3 for 1 hour (Thangnipon et al., 2013) prior to incubation with 0.1--3 mM (usually 2 mM) scopolamine hydrobromide for 24 hours (Pandareesh and Anand, 2013). All experiments were performed using cells from passages 18 to 20.

Cell viability assay {#sec2-3}
--------------------

Cells were incubated with 0.5 mg/mL MTT at 37°C for 3 hours, then supernatant was removed and *A*~570\ nm~ of the blue formazan crystals dissolved in 100 μL of dimethyl sulfoxide (DMSO) was measured with a microplate reader (SpectraMax^®^ 180, Sunnyvale, CA, USA) as described previously (Ivins et al., 1999). Cell viability was presented as the percentage of A570 nm of each sample relative to control.

Reactive oxygen species (ROS) assay {#sec2-4}
-----------------------------------

A DCFH-DAdye assay was used to determine levels of intracellular ROS levels (Lin et al., 2000). In brief, following sequential treatment with PT-3 and scopolamine, cells were incubated with 50 μM DCFH-DA in absolute ethanol for 1 hour in the dark at 37°C. Dichlorofluorescein (DCF) fluorescence (485 nm excitation, 530 nm emission) was quantified using a multimode reader (DTX880, Beckman Coulter, Wals, Austria).

Acetylcholinesterase (AChE) activity assay {#sec2-5}
------------------------------------------

SH-SY5Y cells (5 × 10^5^/mL) were cultured in complete DMEM medium in a 96-well plate for 24 hours, then incubated with 50--200 nM PT-3 for 1 hour, followed by 2 mM scopolamine in serum-free DMEM for further 24 hours. Then cells were washed twice with 100 μL of phosphate-buffered saline (PBS) and incubated at room temperature with 50 μL of 1.3 mM 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) and 50 μL of 1.9 mM acetylthiocholine iodide, both dissolved in PBS (Ellman et al., 1961; Gustafsson et al., 2010). *A*~420\ nm~ of TNB^2--^ was measured at 1, 15, and 30 minutes using a multimode reader (DTX880, Beckman Coulter, Fullerton, CA, USA). Absorbance without substrate or cells was subtracted as background.

Western blot analysis {#sec2-6}
---------------------

Cell lysate proteins (30 μg; determined using Bradford method) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under sulfhydryl-reducing condition and transferred onto polyvinylidene fluoride membrane. Membranes were incubated with the following primary antibodies in TBS-T overnight at 4°C at the specified dilution: rabbit anti-ChAT (1:1,000 dilution), anti-Bcl-2 (1:1,000 dilution), anti-Bax (1:1,000 dilution), anti-activated caspase-3 (1:500 dilution), anti-phospho-p38 (1:1,000 dilution), anti-p38 (1:1,000 dilution), anti-phospho-ERK1/2 (1:1,000 dilution), anti-ERK1/2 (1:1,000), anti-phospho-JNK (1:1,000), anti-JNK (1:1,000), anti-phospho-Akt (1:1,000 dilution), anti-Akt (1:1,000 dilution) or anti-β-actin (1:2,500 dilution) (latter as internal control) antibodies, and then incubated with horseradish peroxidase (HRP)-conjugated secondary anti-rabbit IgG (1:1,000 dilution) antibodies at room temperature for 1 hour. Immunoreactive protein bands were detected using an ECL western blotting substrate (Bio-Rad, Hercules, CA, USA) and recorded on HyperfilmTM (Amersham Pharmacia Biotech). Band density was determined as scanning units using imageJ software (National Institutes of Health, MA, USA) and expression levels were quantified relative to that of β-actin.

Statistical analysis {#sec2-7}
--------------------

One-way analysis of variance (ANOVA) was performed using Prism 5.0a (GraphPad Software, Inc., San Diego, CA, USA) to measure statistical significance of differences, followed by Student-Newman-Keuls test. Data are presented as the mean ± SEM of three independent experiments in triplicate. Results are considered statistically significant at *P*-value \< 0.05.

Results {#sec1-3}
=======

PT-3 attenuated scopolamine-induced cytotoxicity, ROS generation and apoptosis of SH-SY5Y cells {#sec2-8}
-----------------------------------------------------------------------------------------------

Exposure to scopolamine (1--3 mM) for 24 hours significantly decreased human neuroblastoma SH-SY5Y cell viability in a dose-dependent manner (**[Figure 1A](#F1){ref-type="fig"}**), which is in accordance with findings from a previous study (Konar et al., 2011). In all subsequent experiments, 2 M scopolamine resulted in 50.6 ± 2.2% loss in cell viability, which was inhibited by pretreatment with 125--200 nM PT-3 for 1 hour in a concentration-dependent manner (**[Figure 1B](#F1){ref-type="fig"}**). In addition, PT-3 pretreatment ameliorated scopolamine-induced ROS formation over the same concentration range in a dose-dependent manner (**[Figure 1C](#F1){ref-type="fig"}**). Treatment with PT-3 alone had no apparent effect on cell viability or endogenous ROS level.

![*N*-benzylcinnamide (PT-3) pretreatment prevented scopolamine (Sco)-induced cytotoxicity and intracellular reactive oxygen species (ROS) generation in SH-SY5Y cells.\
Cell viability and intracellular ROS levels were determined using MTT assay and DCFH-DA reagent respectively. (A) Viability of SH-SY5Y cells exposed to 2 mM scopolamine. (B) Viability of SH-SY5Y cells treated with 125--200 nM PT-3 prior to 2 mM scopolamine exposure was significantly increased. (C) Intracellular ROS production of SH-SY5Y cells treated with 125--200 nM PT-3 prior to 2 mM scopolamine exposure was significantly decreased. Results are shown as the mean ± SEM of three independent experiments. \*\*\**P* \< 0.001, *vs*. control; \#*P* \< 0.05, \#\#*P* \< 0.01, \#\#\#*P* \< 0.001, *vs*. scopolamine-treated group (one-way analysis of variance followed by Student-Newman-Keuls test). (D) Morphology observed under inverted phase-contrast microscopy of untreated SH-SY5Y cells. (E) Presence of moribund SH-SY5Y cells (arrows) following 2 mM scopolamine treatment. (F) Prior treatment with 150 nM PT-3 restored neurites of SH-SY5Y cells (arrowheads) subjected to 2 mM scopolamine treatment. The insets in D--F are higher magnification views of SH-SY5Y cells. Scale bar: 50 μm.](NRR-12-1492-g001){#F1}

An inverted phase-contrast microscopy revealed that live cells presented shrinkage and cell death (apoptosis) of SH-SY5Y cells following scopolamine exposure, which were prevented by PT-3 pretreatment (**Figure [1D](#F1){ref-type="fig"}--[F](#F1){ref-type="fig"}**). Cell apoptosis was confirmed by the presence of activated caspase-3 (**[Figure 2B](#F2){ref-type="fig"}**) and elevated Bax/Bcl-2 ratio (**[Figure 2C](#F2){ref-type="fig"}**), which again were diminished by PT-3 (200 nM) pretreatment.

![*N*-benzylcinnamide (PT-3) pretreatment prevented scopolamine (Sco)-induced reduction of choline acetyltransferase (ChAT) activity and induction of pro-apoptosis events in SH-SY5Y cells.\
Cells were treated with PT-3 and Sco as described in legend to Figure 1. ChAT activity, activated caspase-3, Bax and Bcl-2 levels were determined by western blot analysis (upper panels). PT-3 pretreatment increased ChAT activity (A), and reduced activated caspase-3 (B) and Bax/Bcl-2 (C) levels. Results are shown as the mean ± SEM of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, *vs*. control group; \#\#\#*P* \< 0.001, *vs*. Sco treated group (one-way analysis of variance followed by Student-Newman-Keuls test). Con: Control.](NRR-12-1492-g002){#F2}

PT-3 suppressed AChE activity but restored ChAT activity in scopolamine-treated SH-SY5Y cells {#sec2-9}
---------------------------------------------------------------------------------------------

As scopolamine upregulated AChE activity in rat PC12 cells (Pandareesh and Anand, 2013), a similar phenomenon was observed when SH-SY5Y cells were treated with 2 mM scopolamine, resulting in 150.5 ± 3.5%, 131.7 ± 2.1%, and 113.4 ± 1.5% increase in AChE activity compared to untreated control when assayed for 1, 15 and 30 minutes, respectively (**[Figure 3](#F3){ref-type="fig"}**), which, as expected, was prevented by PT-3 (50--200 nM) pretreatment. PT-3 restored ChAT activity, reduced by scopolamine, with 1.5 ± 0.16-fold increase in ChAT activity compared to control cells at the highest (200 nM) PT-3 concentration used (**[Figure 2A](#F2){ref-type="fig"}**).

![*N*-benzylcinnamide (PT-3) pretreatment reversed scopolamine (Sco)-induced elevation of acetylcholinesterase (AChE) activity in SH-SY5Y cells.\
Cells were treated with PT-3 and Sco as described in legend to Figure 1. AChE activity was measured by hydrolysis of acetylthiocholine. PT-3 treatment reduced AChE activity determined at 1, 15 and 30 minutes (min), respectively. Results are shown as the mean ± SEM of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, *vs*. control group; \#\#\#*P* \< 0.001, *vs*. Sco-treated group (one-way analysis of variance followed by Student-Newman-Keuls test).](NRR-12-1492-g003){#F3}

PT-3 modulated p38 and JNK pathways in SH-SY5Y cells exposed to scopolamine {#sec2-10}
---------------------------------------------------------------------------

Scopolamine activated redox-responsive cell signaling pathways, such as oxidative stress, inflammation, and cell death (Foyet et al., 2015). In order to identify the pathway(s) involved in the situation of SH-SY5Y cells, western blot analysis was employed to identify key signature factors of activated signaling pathways. Exposure to 2 mM scopolamine resulted in 1.6-fold increase in phospho-p38/p38 ratio over untreated control SH-SY5Y cells, and this was restored to near control value by prior incubation with 100--150 nM PT-3, but only to 50.2 ± 1.8% of control with 200 nM PT-3 (**[Figure 4A](#F4){ref-type="fig"}**). Whereas 2 mM scopolamine reduced phospho-JNK/JNK ratio to 75.4 ± 2.4% of control cells, which was further reduced by 100 and 150 nM PT-3 pretreatment (**Figure [4A](#F4){ref-type="fig"}**, **[B](#F4){ref-type="fig"}**). However, phosphorylation of ERK1/2 and Akt was not affected (**Figure [4C](#F4){ref-type="fig"}**, **[D](#F4){ref-type="fig"}**).

![*N*-benzylcinnamide (PT-3) pretreatment reversed scopolamine (Sco)-induced upregulation of phosphorylated p38 (p-p38) and downregulation of phosphorylated JNK (p-JNK), but did not affect phosphorylation of ERK1/2 and Akt in SH-SY5Y cells (western blot analysis).\
Cells were treated with PT-3 and Sco as described in legend to Figure 1. Levels of p38, p-p38, JNK, p-JNK, ERK1/2, p-ERK1/2, Akt, and p-Akt were determined by western blot analysis (upper panels). (A) Phospho-p38/p38 ratio. (B) Phospho-JNK/JNK ratio. (C) Phospho-ERK1/2/ERK1/2. (D) p-Akt/Akt ratio. Results are shown as the mean ± SEM of three independent experiments. \*\**P* \< 0.01, \*\*\**P* \< 0.001, *vs*. control group; \#*P* \< 0.05, \#\#*P* \< 0.01, \#\#\#*P* \< 0.001, *vs*. Sco-treated group (one-way analysis of variance followed by Student-Newman-Keuls test). Con: Control.](NRR-12-1492-g004){#F4}

Discussion {#sec1-4}
==========

SH-SY5Y cells were chosen for study as they are commonly used as models to investigate *in vitro* neuronal function (Forster et al., 2016) and to assess pharmacological and toxicological potential of AChE inhibitors (Kanhed et al., 2015; Santillo and Liu, 2015). In a previous study (Zhang et al., 2016), scopolamine-induced ROS formation and cellular apoptosis (*via* the classical Bax/Bcl-2 pathway) in SH-SY5Y cells were ameliorated by pretreatment with PT-3. PT-3 manifests antioxidant property (Thangnipon et al., 2013). C6 glioma cells pre-treated with 0.5--2 μM lactucopicrin, a sesquiterpene lactone derived from *Lactuca virosa* and *Cichorium intybus*, have reduced 2′,7′-dichlorofluorescein toxicity induced by 3 mM scopolamine (Venkatesan et al., 2016).

Interestingly, PT-3 pretreatment was capable of suppressing scopolamine-stimulated SH-SY5Y AChE activity. Xian et al. (2015) reported that Honokiol, a lignin from the bark of *Magnolia officinalis*, decreases AChE activity in brain tissues of scopolamine-treated mice. Honokiol contains two phenolic groups, which can exhibit antioxidant property similar to PT-3 (Dikalov et al., 2008).

There is evidence that undifferentiated or differentiated SH-SY5Y cells contain AChR mRNA (Korecka et al., 2013). In this study, PT-3 restored ChAT activity in SH-SY5Y cells that had been reduced by scopolamine, probably by increasing ChAT expression and thereby restoring cholinergic cell function. This property is not confined to PT-3 as Lim et al. (2016) recently demonstrated that curcumin, a natural antioxidant, increases immunoreactive ChAT level in scopolamine-treated mouse hippocampus and improves learning impaired by scopolamine insult.

The activation of p38 and JNK signalling pathways is associated with cellular stress and pro-inflammatory responses (Davis, 2000). Scopolamine induces a number of pathological phenomena associated with neurodegenerative diseases linked to memory decline, including increased oxidative stress, impaired antioxidative defence system and mitochondrial dysfunction (Wong-Guerra et al., 2017). Additionally, JNK and p38 are stress-activated MAP kinases preferentially activated by cell stress-inducing signals, including oxidative stress, environmental stress and toxic chemical insults. Sustained activation of JNK or p38 is implicated in the induction of many forms of neuronal apoptosis in response to a variety of cellular injuries (Wong-Guerra et al., 2017). In scopolamine-treated SH-SY5Y cells, PT-3 inhibits phosphorylation of p38 and JNK, as have been observed in rat primary cultures and human mesenchymal stem cells (Thangnipon et al., 2013, 2016). Although low doses of PT-3 (100--150 nM) inhibited scopolamine-induced cytotoxicity *via* inactivation of JNK, surprisingly high dose of PT-3 (200 nM) enhanced JNK activation (but lower than that in control cells) as has been reported by Shi et al. (2009). In that study, low concentrations (50--100 μg/mL) of EGb761, an extract from *Ginkgo* biloba leaves, inhibits H~2~O~2~-induced cell apoptosis *via* suppression of JNK and caspase-3 activation while high concentrations (250--500 μg/mL) enhance JNK phosphorylation. It is worth noting that pre-treatment with a number of natural phenolic compounds show similar effects on p38 and JNK pathways in oxidant stressed SH-SY5Y cells (Dhanalakshmi et al., 2015; Zhu et al., 2015).

ROS plays a critical role in cell signalling, particularly in redox mechanisms involved in apoptosis, such as the mitochondria-to-cytosol release of cytochrome c, a central event in apoptosis initiation (Circu and Aw, 2010). Interestingly, a *Liriope platyphylla* extract exerts neuroprotective effects against H~2~O~2~ by modulating only p38 and not ERK in SH-SY5Y cells (Park et al., 2015). In addition, p38 inhibitor SB203580 blocks cell loss in H~2~O~2~-treated SH-SY5Y cells (Park et al., 2015). Thus, in SH-SY5Y cells, H~2~O~2~ requires p38 activation for cytotoxicity.

Lee et al. (2005) suggested that baicalein, a flavonoid from *Scutellaria* root, induces a significant reduction in phospho-JNK level of 6-hydroxydopamine-induced neuronal cell death. They also found that ERK and Akt pathways are not altered by scopolamine treatment. These pathways are responsible for cell proliferation, cell differentiation and cell survival (Junttila et al., 2008). Similarly, Voleti et al. (2013) found a low dose of scopolamine treatment (25 μg/kg) does not disturb activated ERK level and has a minimal effect on phospho-Akt in cultured rat pyramidal neurons. Gunjima et al. (2014) reported a similar observation of protection by 3,4-dihydroxybenzalacetone, a catechol-containing compound isolated from *Inonotus obliquus* (persoon) Pilat, against 6-hydroxydopamine toxicity in SH-SY5Y cells that is not affected by ERK inhibitor PD98059. Similarly, Wang et al. (2014) demonstrated that glycyrrhizic acid, a major compound of *Glycyrrhiza radix*, alone or in combination with 20 mM glutamate, has no effect on phospho-Akt level in PC12 cells.
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